I think NEU are setting themselves for the largest TO value possible, taking our current indications to ph 2 only and adding indications they believe are possibilities with the known method of action.
This aligns with my view of all Jon’s previous advice, and Neurens quest to link relevant indications across the spectrum, irrespective of gene mutation.
Jon was stressing the platform link today, which he believes has been answered.
The only question remaining for me is how many additional possible indications can be added before a meaningful takeover offer occurs, and how long do they hold out to prove these.
I think NEU are setting themselves for the largest TO value...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.00 |
Change
-0.190(0.99%) |
Mkt cap ! $2.418B | |||
| Open | High | Low | Value | Volume |
| $18.98 | $19.15 | $18.90 | $2.753M | 145.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 140 | $18.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.00 | 178 | 12 |
View Market Depth
| Last trade - 11.36am 02/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |